Torl Biotherapeutics
Torl Biotherapeutics raises $96M Series C at $500M valuation
Quick Facts
Torl Biotherapeutics: Series C Funding Round
Torl Biotherapeutics has successfully raised $96M in Series C funding, reaching a valuation of $500M.
Company Overview
Antibody-based immunotherapies for cancer patients
Funding Details
The Series C round was led by Cormorant Asset Management, with participation from BVF Partners.
Company Information
- Headquarters: Los Angeles, CA
- Founded: 2019
- Employees: 90+
- Category: Biotech
Investment
Torl Biotherapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Cormorant Asset Management: Verified investor in Series C
- BVF Partners: Verified investor in Series C
Key Investors
About the Author
Related Company Reports
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
Expedition Therapeutics raises $165M Series A at $700M valuation
Expedition Therapeutics raises $165M in Series A at $700M valuation. Developer of therapies for inflammatory and respiratory diseases...